Pacira BioSciences (PCRX) grants CAO 54,546 RSUs vesting from 2027

Rhea-AI Filing Summary

Pacira BioSciences Chief Administrative Officer Kristen Williams received an equity award of 54,546 shares of common stock on February 11, 2026. The award is in the form of restricted stock units granted at a price of $0 per share, described as a grant, award, or other acquisition.

These restricted stock units vest in four equal annual installments beginning on February 15, 2027, as long as she remains in continuous service with the company on each vesting date. Each unit represents the right to receive one share of Pacira common stock. Following this grant, Williams beneficially owns 185,849 shares of Pacira common stock directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider WILLIAMS KRISTEN

Role Chief Administrative Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	54,546	$0.00	--

Holdings After Transaction: Common Stock — 185,849 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WILLIAMS KRISTEN

(Last) (First) (Middle)

C/O PACIRA BIOSCIENCES, INC.

2000 SIERRA POINT PARKWAY, SUITE 900

(Street)

BRISBANE CA 94005

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Pacira BioSciences, Inc. [ PCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Administrative Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/11/2026		A		54,546(1)	A	$0	185,849	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units that vest in four equal annual installments beginning on February 15, 2027, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

Remarks:

	/s/ Kristen Williams	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Pacira BioSciences (PCRX) report for Kristen Williams?

Pacira BioSciences reported that Chief Administrative Officer Kristen Williams received a grant of 54,546 restricted stock units of common stock on February 11, 2026. The Form 4 describes this as a grant, award, or other acquisition at a price of $0 per share.

How many Pacira (PCRX) shares does Kristen Williams own after this Form 4 grant?

After the reported grant, Kristen Williams beneficially owns 185,849 shares of Pacira common stock. This total reflects her direct ownership following the award of 54,546 restricted stock units disclosed for the February 11, 2026 transaction.

What are the vesting terms of Kristen Williams’ Pacira (PCRX) restricted stock units?

The 54,546 restricted stock units vest in four equal annual installments starting February 15, 2027. Vesting requires that Kristen Williams remain in continuous service with Pacira as of each vesting date, aligning the award with ongoing employment.

What does each restricted stock unit represent in the Pacira (PCRX) Form 4 filing?

Each restricted stock unit represents the contingent right to receive one share of Pacira’s common stock. Delivery of the underlying shares depends on the units vesting over time and Kristen Williams continuing her service through each specified vesting date.

Was Kristen Williams’ Pacira (PCRX) equity grant a purchase on the open market?

No, the Form 4 classifies the transaction under code “A,” meaning grant, award, or other acquisition, at a price of $0 per share. This indicates an equity compensation grant rather than an open-market stock purchase or sale.